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Abstract
Objective: Abnormalities in the regulation of natriuretic peptides (NP) associated with major diseases such as hypertension, heart
failure, and diabetes mellitus (DM) have been reported. We investigated levels of mRNA for the vasodilator C-type natriuretic peptide
(CNP) in the renal cortex of streptozotocin (STZ)-diabetic rats and the inﬂuence of an angiotensin II inhibition. Methods: DM was
induced in Wistar rats by a single STZ injection. Rats were kept for 12 weeks. Additionally, the inﬂuence of the ACE inhibitor ramipril
(Ram: 3 mg/kg/day) and the AT1 receptor antagonist losartan (Los: 20 mg/kg/day) on CNP expression in the STZ-diabetic and control
groups was studied (each group n56). Animals were characterized by their mean arterial blood pressure, plasma glucose levels, and renal
function (each group n59). After extraction of total renal cortical RNA, CNP expression was analyzed by Northern blots. Results: Renal
function was impaired in STZ-diabetic rats which has been improved by Ram and Los treatment. Untreated STZ-diabetic rats showed no
difference in renal CNP expression compared to untreated controls. Ram and Los treatments led to an increase in renal cortical CNP
mRNA in both diabetic and non-diabetic rats. This effect was weaker in STZ-diabetic rats (Ram: control 5.4-fold, STZ 3.5-fold; Los:
control 4.2-fold, STZ 1.9-fold). Conclusion: These results clearly demonstrate a direct regulatory effect of the renin–angiotensin system
(RAS) on renal mRNA levels of CNP.We suggest that RAS inhibition not only prevents the generation of angiotensin II (AngII) but also
leads to a stimulation of CNP expression.We conclude that AngII suppresses CNP expression via the AT1 receptor and this mechanism is
impaired in STZ-diabetic rats. Ó 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction shear stress [2] and septic shock [3]. CNP itself is
discussed as an endothelium-derived vasodilator [3], a
C-type natriuretic peptide (CNP) is a 22-amino acid selective cardiovascular peptide [4], a growth inhibitor of
peptide that shows a high structural homology to the two vascular smooth muscle cells [5], and a modulator of
other members of the natriuretic peptide family, atrial ACTH-induced aldosterone secretion [6]. First identiﬁed in
(ANP) and brain (BNP) natriuretic peptide. Whereas ANP the porcine brain [7], CNP expression could be also
and BNP are secreted in an endocrine fashion mainly from detected in the human endothelium [8] and kidney, includ-
the heart and are ligands for the natriuretic peptide receptor ing glomeruli and renal vasculature as well as walls of
A (GC-A), a guanylyl-cyclase-coupled receptor on the cell large extrarenal vessels [6]. The biological role of CNP in
membrane, C-type natriuretic peptide acts predominantly the kidney is not fully understood, but the existence of a
in an autocrine/paracrine fashion and binds speciﬁcally to glomerular CNP system that may regulate tissue homeosta-
the natriuretic peptide receptor B (GC-B) [1]. sis and control mesangial cell proliferation has been
It was shown that CNP-precursor release is triggered by proposed [9].
Little is known about the renal pathophysiological
function of CNP. In experimental renal mesangioprolifera- *Corresponding author. Tel.: 149-30-8445-4258; fax: 149-30-8445-
4648.
E-mail address: walther@ukbf.fu-berlin.de (T. Walther). Time for primary review 20 days.
0008-6363/01/$ – see front matter Ó 2001 Elsevier Science B.V. All rights reserved.
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tive syndromes, CNP treatment led to renal protective mg/kg) after implanting femoral arterial and venous
effects including inhibition of mesangial cell proliferation catheters [10]). Finally, mean arterial pressure (MAP) was
and matrix accumulation [9]. Since nothing was known measured in the conscious state via the arterial catheter
about CNP regulation in diabetic nephropathy, which is (each group n59), as previously described [11]. At the end
also accompanied by mesangial cell proliferation, we of the study (12th week), these rats were placed in
investigated the renal cortical expression of CNP in metabolic cages and urine was collected for 24 h to
streptozotocin (STZ)-diabetic rats for 12 weeks and in a measure total protein excretion using the pyrogallol red
control group of non-diabetic rats. At present, STZ treat- method (Analyticon, Germany).
ment currently provides the best characterized model for
type I diabetes mellitus (DM) in rats. Additionally, CNP 2.2. CNP detection
expression under either an angiotensin-converting enzyme
inhibitor (ACEI) or an AT1 receptor antagonist was To determine renal cortical RNA expression, six anaes-
investigated in both groups to clarify the renal interaction thetized rats of groups A–F were exsanguinated and the
between the renin–angiotensin system (RAS) and CNP. kidneys excised. Renal cortices were macroscopically
separated from renal medullae and rapidly frozen in liquid
nitrogen.
2. Methods Northern blot analysis of renal cortices was performed
after homogenisation and total RNA extraction using the
2.1. Animal experiments Trizol reagent (Gibco, Germany) according to the manu-
facturer’s directions. For each blot, 20 mg of total RNA
Experiments were performed in conscious male Wistar was loaded per lane. A CNP cDNA fragment with the
rats weighing 300–330 g (Dr Karl Thomae, Germany). length of 369 bp was ampliﬁed via the PCR method and
This research was in compliance with the Guide for the sub cloned in a T-vector (Promega). This probe or a 250
Care and Use of Laboratory Animals published by the cDNA speciﬁc for b-actin mRNA as a housekeeping gene
OPRR (Ofﬁce for Protection against Research Risks) of were radiolabeled and hybridised with the blot. After a
the US National Institutes of Health, Washington, DC washing procedure, the signals were analysed by a FUJIX
(NIH Publication No. 85-23, revised 1996) and the institu- BAS 2000 Phosphor-Imager system (Raytest,
tional Animal Ethics Committee. To prevent any inﬂuence Straubenhardt, Germany). Quantitative analysis was per-
of a high protein intake on renal CNP expression and formed by measuring the intensity of the CNP bands
kidney function, the diabetic rats were pair-fed with normalised by the intensity of the b-actin bands.
control animals in the present study.
DM was induced by a single intraperitoneal injection of 2.3. Statistical analysis of data
STZ (70 mg/kg, diluted with 0.4 ml of sodium citrate
buffer [0.1 M, pH 4.5]; Sigma Chemical Co., Germany), All data ate expressed as means6S.E.M. Data were
the single-shot STZ injection providing the best character- analysed using a two-way analysis of variance (ANOVA)
ized model for type I DM model in rats. in conjunction with Student’s t-test. P values ,0.05 were
Hyperglycemia was conﬁrmed 48 h later by a reﬂect- accepted as signiﬁcant.
ance meter (Acutrend, Boehringer Mannheim, Germany).
Non-diabetic rats were used as controls (A), treated with
Ram (ACEI; 3 mg/kg/day per gavage) (B), or treated with 3. Results
Los (AT1 receptor antagonist; 20 mg/kg/day per gavage)
(C). In a pilot experiment, these doses have been demon- 3.1. Characteristics of diabetic rats
strated to inhibit 90% of the vasopressor effect of exogen-
ous AngI (Ram) or AngII (Los). As summarised in Table 1, all groups of STZ-diabetic
The STZ-diabetic rats were randomized to receive one rats developed severe hyperglycaemia after 12 weeks. The
of the following three regimens for a period of 12 weeks: increase was signiﬁcant compared to controls (P,0.01).
no treatment (D), Ram (E), or Los (F). This time span was MAP did not differ signiﬁcantly between treated and
chosen because rats are known to develop severe diabetic untreated non-diabetic rats, and STZ-diabetic rats. Diabetic
nephropathy accompanied by increased glomerular basal rats treated with Ram or Los showed no signiﬁcant
membrane thickness, mesangial cell proliferation and changes in MAP compared to controls (Table 1).
glomerular matrix accumulation 12 weeks after STZ All treatment groups of STZ-diabetic rats showed
injection [12]. Throughout the 12-week study period, STZ- similar blood glucose and MAP values. However, GFR
treated rats (n515 per group) displayed severe hy- and renal protein excretion levels differed. Although all
perglycaemia (.600 mg/dl). groups of STZ diabetic rats showed a marked GFR
After the 11th week, glomerular ﬁltration rate (GFR) reduction and an increase in urinary protein excretion
was measured by a single inulin injection method (800 compared to non-diabetic animals, Ram- or Los-treated
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Table 1
Effect of ramipril or losartan on renal function (glomerular ﬁltration rate [GFR]; urine protein excretion), mean arterial pressure (MAP), and blood glucose
levels in normoglycaemic rats or 12 weeks after STZ injection (n59)
Control Control Control STZ STZ STZ
ramipril losartan ramipril losartan
Blood glucose 140612 177623 135622 6206140* 588699* 5896136
(mg/dl)
MAP 9861.2 9662.2 9561.6 9660.9 9460.8 9361.6
(mmHg)
[[ GFR 3.260.3 3.760.3 3.561.3 1.660.1* 2.260.6* 2.060.5*
(ml/min)
Urine protein
[[ (mg/24 h) 76.768 85.467 84.069 226622* 146617* 115614*
[ Values are means6S.E.M. * P,0.05 vs. control, P,0.05 vs. STZ.
STZ-diabetic rats had an improved GFR (P,0.05) and a contrast to renal ANP [14], the development of diabetic
reduced urinary protein excretion compared to untreated nephropathy, which is characterised by increased glomeru-
STZ-diabetic rats (P,0.01). lar pressure and mesangial cell proliferation does not
inﬂuence CNP gene expression after 12 weeks, although
3.2. CNP expression the peptide is a vasodilator and antiproliferative agent [9].
Additionally, under diabetic conditions, renal CNP
CNP expression was analysed by Northern blot analysis mRNA is regulated differently from cardiac CNP gene
(Fig. 1). RNA was detectable for all samples using the expression, which we recently found to be downregulated
b-actin probe (Fig. 1A). In untreated STZ-diabetic rats no in diabetic cardiopathy [15].
difference in renal cortical CNP expression was found Moreover, an inhibition of the RAS in control and
compared to controls. Additionally, we studied in both diabetic rats led to a signiﬁcant increase of CNP expres-
control and STZ-diabetic rats the inﬂuence of Ram and sion. The weaker increase in CNP mRNA in STZ-diabetic
Los on CNP expression (each group n56). Both treatments rats compared to controls after RAS inhibition may
led to an increase of renal cortical CNP mRNA in all indicate diabetic-induced interstitial changes including cell
experimental groups (Fig. 1B). The CNP-mRNA levels atrophy and ﬁbrosis. However, since an up regulation of
were more pronounced after ACEI than after AT1 receptor CNP mRNA by AT1 blockade is a direct proof for CNP
blockade, though this effect was weaker in STZ-diabetic mRNA suppression by A II, we are the ﬁrst to demonstrate
than in control kidneys (Ram: control 5.4-fold, STZ 3.5- that AngII down regulates renal CNP expression under
fold; Los: control 4.2-fold, STZ 1.9-fold). physiological and diabetic conditions.
Since CNP expression was more pronounced under
ACEI treatment than under AT1 receptor blockade, either
4. Discussion ACE itself triggers CNP mRNA to a small degree via
angiotensin-independent pathways, or the angiotensin-re-
The aim of the study was to investigate renal cortical ceptor AT2 is also involved in the regulation of CNP
CNP mRNA in STZ-diabetic rats compared to controls and expression. In addition, since plasma concentrations of
the inﬂuence of an ACEI or an AT1 receptor antagonist on CNP were not signiﬁcantly affected by AngII infusion
CNP expression under diabetic and control conditions. [16], whereas a renal RAS blockade in our study led to
Since plasma, renal and urinary CNP peptide concen- augmented CNP-mRNA concentrations in kidney, our
trations are inﬂuenced by glomerular hypoﬁltration and ﬁndings give a new indication of an autocrine function of
proteinuria in our DM type I rat model, the detection of CNP. One further indication that CNP is involved in the
renal cortical CNP mRNA is a more speciﬁc marker of beneﬁcial effects of angiotensin inhibition using ACEI or
CNP regulation than measurement of peptide concentra- an AT1 antagonist is the inhibitory effect of AngII on the
tions. growth arrest-speciﬁc homeobox (Gax) gene, a factor
Our results are the ﬁrst to demonstrate that renal CNP- involved in the suppression of neointima formation, where-
mRNA levels in STZ-diabetic rats with reduced GFR and as CNP up regulates Gax mRNA [17]. In addition, Segawa
glomerular damage indicated by increased urinary protein et al. [18] found that CNP inhibits rat mesangial cell
levels, do not differ from those in to controls with normal proliferation. This is in agreement with studies of Canaan-
¨ renal function 12 weeks after STZ injection. Since Shin et Kuhl et al. [9], showing that CNP treatment inhibits
al. [13] found renal upregulation of CNP mRNA 8 weeks mesangial cell proliferation and matrix accumulation in a
after STZ injection, more severe nephropathy [12] 12 rat model of mesangioproliferative glomerulonephritis in
weeks after the induction of experimental diabetes enables vivo. Therefore, an up regulation of the renal CNP axis
the kidney to upregulate CNP gene expression. Thus, in may also lead to a reduction of renal hypertrophy and
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Fig. 1. Renal cortical CNP expression in control rats without, after Ram, or Los treatment and in diabetic rats without, after Ram, or Los treatment. (A)
Representative Northern blot assay showing the CNP signals for three samples per group. (B) Quantitation of CNP-mRNA expression after
autoradiographic signal analysis (n56). Data are shown as multiples after normalization to b-actin mRNA levels.Values are means6S.E.M. * P,0.01 vs.
[ control, P,0.01 vs. STZ controls.
mesangial proliferation under diabetic conditions. CNP peptide level, since Davidson et al. [20] could show that
seems not to be an inhibitor of the physiological actions of CNP is an endogenous inhibitor of vascular ACE activity.
AngII, such as pulmonary pressor effects and stimulation Therefore, CNP stimulation may lead to an additional
of aldosterone secretion [19], but an inhibitor of the AngII down regulation of the RAS after an initial blockade of the
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tiﬁed in porcine brain. Biochem Biophys Res Commun AngII activity. Thus, one of the physiological functions of
1990;168:863–870. CNP up regulation under pathophysiological conditions
[8] Stingo AJ, Clavell AL, Heublein DM,Wie CM, Pittelkow R, Burnett
could be the prevention of negative actions of AngII. JC. Presence of C-type natriuretic peptide in cultured human
Therefore, an impaired increase of CNP after RAS bloc- endothelial cells and plasma. Am J Physiol 1992;263:H1318–
kade under diabetic conditions could be a reason for the H1321.
¨ [9] Cannan-Kuhl S, Ostendorf T, Zander K, Koch KM, Floege J. C-type impaired renal function in DM under ACEI compared to
natriuretic peptide inhibits mesangial cell proliferation and matrix non-diabetic rats. Since Igaki et al. [21] demonstrated an
accumulation in vivo. Kidney Int 1998;53:1143–1151.
increased GFR after CNP infusion in healthy humans and ¨ [10] Kuhnle HF, Linzmeier P, Doerge L. Determination of glomerular
patients with chronic renal failure, an elevated CNP level ﬁltration rate in rats. In: Gretz N, Strauch M, editors, Experimental
by itself could be beneﬁcial for the diabetic renal function. and genetic rat models of chronic renal failure, Basel: Karger, 1989,
pp. 331–336. Our results are the ﬁrst to demonstrate a direct regulatory
[11] Stauss B, Itoi K, Stauss H, Unger Th. A novel inexpensive computer effect of RAS on renal CNP expression. We also suggest
system to record and analyze hemodynamic data in conscious
that AngII suppresses CNP expression via the AT1 re- animals. Eur J Pharmacol 1990;183:863–864.
ceptor. This effect is reduced in STZ-diabetic rats. How- [12] Hirose K, Osterby R, Nozawa M, Gundersen HJ. Development of
ever, RAS inhibition not only prevents the generation of glomerular lesions in experimental long-term diabetes in the rat.
Kidney Int 1982;21(5):889–895. AngII but also leads to a stimulation of CNP expression.
[13] Shin SJ, Wen ID, Lee YJ, Chen IH, Tsai JH. Increased C-type Further experiments have to show whether this stimulation
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